Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025 (Earliest event reported)
Reporting Period: Events occurring between May 19, 2025, and August 12, 2025.
Key Financial Metrics
This filing does not provide a comprehensive set of financial statements. Specific metrics mentioned include:
- Cash Raised: Approximately $6.6 million raised in July 2025 via an At-the-Market (ATM) offering.
- Stockholders' Equity: The Company asserts it has at least $2,500,000 in stockholders' equity as of June 30, 2025, inclusive of the July ATM proceeds.
- Revenue, Profit, Margins, Debt: The filing text does not provide clear values for revenue, net income, operating margins, or debt levels.
Material Changes
- Bylaw Amendment: On August 12, 2025, the Board amended Section 2.7 of the Bylaws to lower the quorum requirement for stockholder meetings from a majority (50% + 1) to at least one-third (33.3%) of the voting power of stock issued and outstanding.
- Listing Compliance: The Company resolved a deficiency notice from Nasdaq regarding the minimum stockholders' equity requirement ($2.5 million) for continued listing on The Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
Nasdaq Compliance Status: On August 8, 2025, Nasdaq confirmed the Company complies with the Stockholders' Equity Requirement based on the June 30, 2025, 10-Q and July ATM proceeds.
Risks and Contingencies:
- Delisting Risk: Nasdaq warned that if the Company fails to evidence compliance in its next periodic report, it may be subject to delisting.
- Appeal Process: In the event of a future non-compliance determination, the Company may appeal to a Hearings Panel.
Investor Verification Checklist
- Verify the exact stockholders' equity balance in the most recent Form 10-Q (quarter ended June 30, 2025) to confirm the $2.5 million threshold.
- Review the full text of the Bylaw Amendment (Exhibit 3.1) to understand the implications of the reduced quorum requirement on corporate governance.
- Monitor upcoming periodic reports to ensure continued compliance with Nasdaq Listing Rule 5550(b)(1) to avoid delisting proceedings.
- Confirm the utilization of the $6.6 million raised in July 2025 to assess liquidity runway.